The STOP Nitazenes Act would amend the federal Controlled Substances Act to permanently place 2-benzylbenzimidazole opioids, commonly known as nitazenes, into Schedule I. The bill defines the covered substances broadly to include any material containing a 2-benzylbenzimidazole opioid, its salts, isomers, and salts of isomers, as well as related compounds that fit specified structural criteria or act as mu-opioid receptor agonists. It also expressly lists several named nitazene compounds, including etonitazene, isotonitazene, metonitazene, protonitazene, and others.
In addition to the scheduling change, the bill provides that any nitazene substance already temporarily scheduled under existing law would be deemed permanently scheduled upon enactment. It directs the Attorney General to issue implementing rules within one year, allows those rules to take effect immediately as interim final rules, and requires an opportunity for public comment and hearing before a final rule is issued. The legislation is designed to strengthen federal enforcement tools against a class of synthetic opioids associated with overdose risk and illicit drug trafficking.
Impact
If enacted, the bill would expand and make permanent federal Schedule I control over nitazenes, subjecting covered substances to the strictest federal controlled-substance restrictions and enforcement penalties under the Controlled Substances Act. It would affect manufacturers, distributors, traffickers, researchers, and law enforcement by clarifying that a broad set of nitazene-related compounds are illegal unless specifically exempted or separately scheduled. The bill would also require the Department of Justice to implement the change through rulemaking and would convert any temporary scheduling of these substances into permanent scheduling.
Sentiment
The available context suggests generally favorable sentiment toward the bill, with the measure being forwarded by subcommittee to the full committee by voice vote and no recorded votes or opposition in the provided materials. The lack of recorded dissent or transcript debate indicates the bill was treated as a public-safety and drug-control measure with broad procedural support at this stage. Overall, the tone appears supportive and noncontroversial in committee consideration.
Contention
The main policy issue embedded in the bill is the breadth of the scheduling definition. By covering not only named nitazenes but also structurally related compounds and any substance with mu-opioid receptor agonist activity, the bill could be seen as giving federal authorities wide discretion to capture emerging analogs. Potential concerns for researchers, medical chemists, and civil-liberties advocates would likely center on overbreadth, scientific research restrictions, and the speed of interim final rulemaking. No specific opposition is documented in the provided committee materials, but those are the most likely points of contention.